Searched for
PFIZER PILL
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...- Pfizer scraps weight loss pill after liver injury: What it means for the future of obesity drugs?Pfizer halted development of its weight-loss pill, danuglipron, after liver injury concerns surfaced during trials, impacting its ambition ...
- Rare cases of COVID returning pose questions for Pfizer pillPaxlovid has become the go-to option against COVID-19 because of its at-home convenience and impressive results in heading off severe disea...
- Covid pills are here, but they aren't for everyone. Find out if you should take this medicationThe pills have to be started as soon as possible, within five days of the start of symptoms.
- World Health Organization 'strongly recommends' Pfizer's COVID-19 pillUS pharma giant Pfizer's combination of nirmatrelvir and ritonavir was the "superior choice" of treatment for unvaccinated, elderly or immu...
- China approves use of Pfizer's COVID drug PaxlovidThe National Medical Products Administration said Paxlovid is approved to treat adults who have mild to moderate COVID-19 and high risk of ...
- Pfizer's COVID product sales to top $50 billion this year, investors want moreAlthough Pfizer raised its forecast for the vaccine, developed with Germany's BioNTech SE, by $1 billion to $32 billion, the drugmaker caut...
- How does Merck's COVID-19 pill compare to Pfizer's?Merck in November said its full trial results showed that molnupiravir lowered the chance of hospitalization or death by about 30% in patie...
- SEC no to clinical trial waiver for Pfizer's Covid pillThe SEC asked the companies to conduct bioavailability and bioequivalence (BA/BE) studies and submit safety data at its meeting on Friday, ...
- EU regulator set to rule on Pfizer COVID pill by end-Jan, ahead of Merck - sourceThe EMA's review of Merck's pill, developed with Ridgeback Biotherapeutics, is taking longer than Pfizer's because Merck released trial dat...
- Newly infected Covid-19 patients have two new home treatment options, but there's a catchYou'll need a prescription first from a doctor or other authorized health worker.
- U.S. FDA authorizes Merck's at-home antiviral COVID-19 pillMerck's drug, molnupiravir, developed with Ridgeback Biotherapeutics, was shown to reduce hospitalizations and deaths by around 30% in a cl...
- Pfizer pill becomes 1st US-authorized home COVID treatmentData from Pfizer's clinical trial showed its two-drug antiviral regimen was 90% effective in preventing hospitalizations and deaths in pati...
- Pfizer confirms COVID pill's results, potency versus omicronThe Food and Drug Administration is expected to soon rule on whether to authorize Pfizer's pill and a competing pill from Merck, which was ...
- Pfizer to allow generic versions of its COVID-19 pill in 95 countriesThe voluntary licensing agreement between Pfizer and the MPP will allow the United Nations-backed group to grant sub-licenses to qualified ...
- Pfizer says antiviral pill cuts risk of severe COVID-19 by 89%Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, ...
- Set to conquer US, Indian 'Viagras' may give Pfizer a hard timeThe nearing end of Pfizer's patent will open floodgates of the lucrative US market to Indian companies.
- Pfizer recalls 1 million contraceptive medicine packsPfizer recalled 1 mn birth-control packs after discovering that pills were mixed up inside the packages, possibly putting women at risk.
- Pfizer to license generics from India's AurobindoPfizer Inc has agreed to license an array of generic pills and injectable medicines from India's Aurobindo Pharma Ltd as the world's larges...
- Ranbaxy faces another setback in Lipitor battleRanbaxy’s $12bn dream to bust Pfizer’s monopoly over its cholesterol-lowering pill Lipitor has suffered yet another setback with the US Cou...
Load More
